Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment

NCT06217094 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped funding terminated

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: NP-101 (3 g)
DRUG: NP-101 (4.8 g)
DRUG: NP-101 (6 g)

Sponsor

University of Florida

Collaborators

[object Object]
[object Object]